One of the remaining issues is NAFLD patients with T2DM who failed to normalize serum ALT levels by SGLT2 inhibitors, herein defined as “refractory to SGLT2 inhibitor”. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.